GMAB · CIK 0001434265
Genmab A/S
Annual figures as reported, FY2016–FY2025. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Net income
DKK 7.8B
▲ +80.2% vs FY2023
Operating cash flow
DKK 7.8B
▲ +5.3% vs FY2023
Diluted EPS
DKK 121.36
▲ +83.8% vs FY2023
Net income
Annual, as reported
Profitability & returns
quality of earningsReturns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationOperating cash flow
Net cash from operations
Shareholder returns
capital allocationDiluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Growth rates
compounding, annualizedNet income CAGR
+29.4%
5y
Diluted EPS CAGR
+29.0%
5y
Key ratios
derived per fiscal year| Fiscal year | ROE | ROA |
|---|---|---|
| FY2025 | — | — |
| FY2024 | 21.4% | 17.1% |
| FY2023 | 13.8% | 12.3% |
| FY2019 | 15.4% | 14.3% |
| FY2018 | 18.4% | 17.4% |
| FY2017 | 17.6% | — |
| FY2016 | — | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | — | — | — | — | — | — | — | — | — | — | — | — |
| FY2024 | — | — | — | DKK 7.8B | DKK 121.36 | DKK 7.8B | — | DKK 45.8B | DKK 9.1B | DKK 36.7B | — | — |
| FY2023 | — | — | — | DKK 4.4B | DKK 66.02 | DKK 7.4B | — | DKK 35.3B | DKK 3.7B | DKK 31.6B | — | — |
| FY2019 | — | — | — | DKK 2.2B | DKK 34.03 | DKK 1.3B | — | DKK 15.1B | DKK 1.1B | DKK 14.0B | — | — |
| FY2018 | — | — | — | DKK 1.5B | DKK 23.73 | DKK 1.0B | — | DKK 8.5B | DKK 447.0M | DKK 8.0B | — | — |
| FY2017 | — | — | — | DKK 1.1B | DKK 17.77 | DKK 1.6B | — | — | — | DKK 6.3B | — | — |
| FY2016 | — | — | — | — | — | — | — | — | — | DKK 4.8B | — | — |
Latest filings
the most recent regulatory filings6-KForeign issuer report2026-06-29 ↗6-KForeign issuer report2026-06-17 ↗6-KForeign issuer report2026-06-16 ↗6-KForeign issuer report2026-06-15 ↗6-KForeign issuer report2026-06-15 ↗6-KForeign issuer report2026-06-11 ↗6-KForeign issuer report2026-05-29 ↗SCHEDULE 13G/ASEC filing2026-05-15 ↗6-KForeign issuer report2026-05-13 ↗6-KForeign issuer report2026-05-12 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.